STAT3-IN-47
STAT3-IN-47 is an orally active STAT3 inhibitor. STAT3-IN-47 exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells. STAT3-IN-47 suppresses STAT3 activation in vitro. STAT3-IN-47 can be used for the study of solid tumors, especially central nervous system (CNS) malignancies and hepatocellular carcinoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2787548-58-5
- 分子式: C15H8N4O3S
- 分子量:324.31
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
IC50 & Target
[1]|
STAT3 |
体外実験
STAT3-IN-47 (Compound S1) (0.1-10 μM) exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells, with IC50 values of 5.066 μM, 0.8089 μM, 1.970 μM, and 1.412 μM respectively[1].
STAT3-IN-47 (0.1-10 μM) suppresses STAT3 activation in a dose-dependent manner in HeLa, HepG2, U87, and LN229 cells[1].
STAT3-IN-47 (0.5-2 μM) inhibits EGF-induced STAT3 phosphorylation (Y705) in HeLa cells and dose-dependently suppresses IL-6-induced STAT3 phosphorylation (Y705) in HepG2, U87, LN229 cells[1].
STAT3-IN-47 downregulates stemness-associated genes (Nanog, Oct4, β-catenin) in Huh7, LN229, and HepG2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
化学情報
-
CAS 番号 2787548-58-5
-
分子量 324.31
-
分子式 C15H8N4O3S
-
SMILES
O=C(C1=C2OC(/C=N/N3C=NNC3=S)=C1)C4=C(C2=O)C=CC=C4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
STAT3-IN-47 関連分類
HY-178140 関連分類
Powered by Bioz